.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cerilliant
US Department of Justice
Federal Trade Commission
Daiichi Sankyo
Colorcon
Dow
Chinese Patent Office
Queensland Health
Julphar
AstraZeneca

Generated: July 27, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 019668

« Back to Dashboard
NDA 019668 describes CARDURA, which is a drug marketed by Pfizer and is included in two NDAs. It is available from three suppliers. Additional details are available on the CARDURA profile page.

The generic ingredient in CARDURA is doxazosin mesylate. There are thirteen drug master file entries for this compound. Thirty-four suppliers are listed for this compound. Additional details are available on the doxazosin mesylate profile page.

Summary for NDA: 019668

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Cardiovascular Agents
Genitourinary Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 019668

Mechanism of ActionAdrenergic alpha-Antagonists

Suppliers and Packaging for NDA: 019668

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CARDURA
doxazosin mesylate
TABLET;ORAL 019668 NDA Roerig 0049-2750 0049-2750-41 100 BLISTER PACK in 1 CARTON (0049-2750-41) > 1 TABLET in 1 BLISTER PACK
CARDURA
doxazosin mesylate
TABLET;ORAL 019668 NDA Roerig 0049-2750 0049-2750-66 100 TABLET in 1 BOTTLE (0049-2750-66)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 1MG BASE
Approval Date:Nov 2, 1990TE:ABRLD:Yes

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 2MG BASE
Approval Date:Nov 2, 1990TE:ABRLD:Yes

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 4MG BASE
Approval Date:Nov 2, 1990TE:ABRLD:Yes

Expired Orange Book Patents for NDA: 019668

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer
CARDURA
doxazosin mesylate
TABLET;ORAL019668-001Nov 2, 1990► Subscribe► Subscribe
Pfizer
CARDURA
doxazosin mesylate
TABLET;ORAL019668-003Nov 2, 1990► Subscribe► Subscribe
Pfizer
CARDURA
doxazosin mesylate
TABLET;ORAL019668-004Nov 2, 1990► Subscribe► Subscribe
Pfizer
CARDURA
doxazosin mesylate
TABLET;ORAL019668-002Nov 2, 1990► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Colorcon
Express Scripts
Queensland Health
Johnson and Johnson
QuintilesIMS
Fuji
Chinese Patent Office
McKinsey
Cipla
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot